The U.S. FDA has released a new draft guidance for drugmakers to aid them in developing new treatments for obesity. The new document replaces an earlier draft guidance issued in February 2007. The new ...
GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...
The FDA published its first draft guidance on the use of AI in the development of drugs and biological products ...
Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...
In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...
The FDA will decide later this month whether to approve a novel drug for acute pain that could offer a nonaddictive ...
Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Just eight seconds into the start of the 2025 award show season, Nikki Glaser, the host of the 82nd Golden Globes, dubbed the ...
Today's health news includes potential cuts to Medicaid under the Trump administration and the five-year anniversary of Covid ...
Kwame Raoul’s office sent cease and desist letters to five unnamed medical spas in the Chicago area that were allegedly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback